How to cite item

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

	author = {Takashi Kohno and Takashi Nakaoku and Koji Tsuta and Katsuya Tsuchihara and Shingo Matsumoto and Kiyotaka Yoh and Koichi Goto},
	title = {Beyond  ALK-RET, ROS1  and other oncogene fusions in lung cancer},
	journal = {Translational Lung Cancer Research},
	volume = {4},
	number = {2},
	year = {2015},
	keywords = {},
	abstract = {Fusions of the RET and ROS1 protein tyrosine kinase oncogenes with several partner genes were recently identified as new targetable genetic aberrations in cases of non-small cell lung cancer (NSCLC) lacking activating EGFR, KRAS, ALK, BRAF, or HER2 oncogene aberrations. RET and ROS1 fusion-positive tumors are mainly observed in young, female, and/or never smoking patients. Studies based on in vitro and in vivo (i.e., mouse) models and studies of several fusion-positive patients indicate that inhibiting the kinase activity of the RET and ROS1 fusion proteins is a promising therapeutic strategy. Accordingly, there are several ongoing clinical trials aimed at examining the efficacy of tyrosine kinase inhibitors (TKIs) against RET and ROS1 proteins in patients with fusion-positive lung cancer. Other gene fusions (NTRK1, NRG1, and FGFR1/2/3) that are targetable by existing TKIs have also been identified in NSCLCs. Options for personalized lung cancer therapy will be increased with the help of multiplex diagnosis systems able to detect multiple druggable gene fusions.},
	issn = {2226-4477},	url = {}